Synthesis and biological evaluation of some dibenzofuran-piperazine derivatives

References

• McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacol Sci 2003;93:381–96
   PubMed Web of Science ®Google Scholar
• Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. Part I. N Engl J Med 1992;326:242–50
   PubMed Web of Science ®Google Scholar
• Braunwald E, Angiolillo D, Bates E, et al. Antiplatelet therapy and platelet function testing. Clin Cardiol (Suppl. 1) 2008;31:I36
   PubMed Web of Science ®Google Scholar
• Youssef KM, Al-Omar MA, El-Subbagh HI, et al. Synthesis, antiplatelet aggregation activity, and molecular modeling study of novel substituted-piperazine analogues. Med Chem Res 2011;20:898–911
   Web of Science ®Google Scholar
• Nacak Baytas S, Inceler N, Ozkan Y, et al. Novel 1,3-diarylpyrazole acrylamides: synthesis, antiplatelet activity screening, and in silico evaluation studies. Med Chem Res 2013;22:5922–33
   Web of Science ®Google Scholar
• Weksler BB. Antiplatelet agents in stroke prevention. Combination therapy: present and future. Cerebrovasc Dis 2000;10:41–8
   PubMed Web of Science ®Google Scholar
• Mills DC. ADP receptors on platelets. Thromb Haemost 1996;76:835–56
   PubMed Web of Science ®Google Scholar
• Kunapuli SP. Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Trends Pharmacol Sci 1998;19:391–4
   PubMed Web of Science ®Google Scholar
• Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001;8:222–32
   Google Scholar
• Van De Graaff E, Steinhubl SR. Antiplatelet medications and their indications in preventing and treating coronary thrombosis. Ann Med 2000;32:561–71
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119:39S–63S
   PubMed Web of Science ®Google Scholar
• Dogne J-M, de Leval X, Benoit P, et al. Recent advances in antiplatelet agents. Curr Med Chem 2001;9:577–89
   Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71–86
   PubMed Web of Science ®Google Scholar
• Storey F. The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets 2001;12:197–209
   PubMed Web of Science ®Google Scholar
• Berger PB. The thienopyridines in coronary artery disease. Curr Cardiol Rep 1999;1:192–8
   PubMedGoogle Scholar
• McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002;88:711–5
   PubMed Web of Science ®Google Scholar
• Bennett JS. Novel platelet inhibitors. Annu Rev Med 2001;52:161–84
   PubMed Web of Science ®Google Scholar
• Schros K. Antiplatelet drugs: a comparative review. Drugs 1995;50:7–28
   PubMed Web of Science ®Google Scholar
• Hirano T, Yamori Y, Kanai N, et al. The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke. Mol Chem Neuropathol 1992;17:91–102
   PubMedGoogle Scholar
• Murai T, Muraoka K, Saga K, et al. Effect of beraprost sodium on peripheral circulation insufficiency in rats and rabbits. Arzneimittelforschung 1989;39:856–9
   PubMed Web of Science ®Google Scholar
• Nishio S, Nagase H, Kanou K, et al. Research and development of beraprost sodium, a new stable PGI2 analogue. Zasshi Yakugaku 1997;117:509–21
   PubMed Web of Science ®Google Scholar
• Wu TS, Liou MJ, Kuoh CS, et al. Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia. J Nat Prod 1997;60:606–8
   PubMed Web of Science ®Google Scholar
• Verghese J, Liang A, Sidhu PS, et al. First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor Xa. Bioorg Med Chem Lett 2009;19:4126–9
   PubMed Web of Science ®Google Scholar
• Sidhu PS, Liang A, Mehta AY, et al. Rational design of potent, small, synthetic allosteric inhibitors of thrombin. J Med Chem 2011;54:5522–31
   PubMed Web of Science ®Google Scholar
• Abdel Aziz MH, Sidhu PS, Liang A, et al. Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with arg173 of exosite II to induce inhibition. J Med Chem 2011;55:6888–97
   Web of Science ®Google Scholar
• Sidhu PS, Mosier PS, Desai UR. On scaffold hopping: challenges in the discovery of sulfated small molecules as mimetics of glycosaminoglycans. Bioorg Med Chem Lett 2013;23:355–9
   PubMed Web of Science ®Google Scholar
• Sidhu PS, Hamdy MH, Sarkar A, et al. Designing allosteric regulators of thrombin. Exosite 2 features multiple sub-sites that can be targeted by sulfated small molecules for inducing inhibition. J Med Chem 2013;56:5059–70
   PubMed Web of Science ®Google Scholar
• Thalji RK, Aiyar N, Davenport EA, et al. Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists. Bioorg Med Chem Lett 2010;20:4104–7
   PubMed Web of Science ®Google Scholar
• Kikumoto R, Tamao Y, Ohkubo K, et al. Crystal structure of two new biofunctional nonsubstrate type thrombin inhibitors complexed with human α-thrombin. J Med Chem 1980;23:1293–9
   PubMed Web of Science ®Google Scholar
• Wang TC, Chen IL, Kuo DH, Liao CH. Synthesis and cytoxic and antiplatelet activities of dibenzofuran and carbazole-substituted oximes. Helvetica Chim Acta 2004;87:983–90
   Web of Science ®Google Scholar
• Sadashiva CT, Narendra Sharath Chandra JN, Ponnappa KC, et al. Synthesis and efficacy of 1-[bis(4-fluorophenyl)-methyl]piperazine derivatives for acetylcholinesterase inhibition, as a stimulant of central cholinergic neurotransmission in Alzheimer's disease. Bioorg Med Chem Lett 2006;16:932–6
   Web of Science ®Google Scholar
• Yurttaş L, Özkay Y, Kaplancıklı ZA. Design, synthesis and evaluation of new thiazole-piperazines as acetylcholinesterase inhibitors. J Enzyme Inhib Med Chem 2013;28:1040–7
   PubMed Web of Science ®Google Scholar
• Mohammadi-Farani A, Ahmadi A, Nadri H, Aliabadi A. Synthesis, docking and acetylcholinesterase inhibitory assessment of 2-(2-(4-benzylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with potential anti-Alzheimer effects. DARU J Pharm Sci 2013;21:47
   Web of Science ®Google Scholar
• Darias V, Bravo L, Tabares de Nava B, Fraile C. Study of the antiaggregating activity of new phenacyl-piperazine derivatives. Farmaco Sci 1986;41:684–8
   PubMedGoogle Scholar
• Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–9
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95
   PubMed Web of Science ®Google Scholar
• Perry NSL, Houghton PJ, Theobald AE, et al. In-vitro inhibition of human erythrocyte acetylcholine esterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol 2000;52:895–902
   PubMed Web of Science ®Google Scholar
• Lopez-Ortiz M, Monsalvo I, Demare P, et al. Synthesis of ranolazine derivatives containing the (1S,4S)-2,5-diazabicyclo[2.2.1]heptane moiety and their evaluation as vasodilating agents. Chem Biol Drug Des 2014;83:710–20
   PubMed Web of Science ®Google Scholar